STOCK TITAN

Uniqure - QURE STOCK NEWS

Welcome to our dedicated page for Uniqure news (Ticker: QURE), a resource for investors and traders seeking the latest updates and insights on Uniqure stock.

uniQure (QURE) is a leading biotechnology company advancing innovative gene therapies for severe genetic diseases, including hemophilia and Huntington's disease. This dedicated news hub provides investors and stakeholders with timely updates on clinical developments, regulatory milestones, and strategic partnerships.

Access the most comprehensive collection of official press releases, clinical trial progress reports, and financial disclosures directly impacting QURE's trajectory. Our curated feed ensures you never miss critical updates about therapeutic advancements or collaborative ventures with industry leaders like Bristol Myers Squibb.

This resource serves investors seeking material events analysis, researchers tracking gene therapy innovations, and healthcare professionals monitoring treatment breakthroughs. All content is sourced from verified channels to maintain accuracy and compliance with financial reporting standards.

Bookmark this page for streamlined access to uniQure's latest announcements. Check back regularly for real-time updates on one of biotech's most dynamic gene therapy innovators.

Rhea-AI Summary
uniQure receives FDA clearance for gene therapy candidate AMT-260 for refractory MTLE; clinical trial initiation expected in Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.86%
Tags
-
Rhea-AI Summary
uniQure N.V. reported encouraging interim analysis data from a Phase I/II clinical trial of AMT-130 in Huntington's disease, showing preservation of function and clinical benefits. They also announced plans for clinical trials in refractory temporal lobe epilepsy and SOD1-ALS, and the submission of an IND for Fabry disease. The company has a strong cash position of $628.6 million and sold a royalty interest in HEMGENIX® for up to $400 million. They appointed a new Chief Medical Officer and Chief Legal Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.23%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
none
Uniqure

Nasdaq:QURE

QURE Rankings

QURE Stock Data

495.88M
48.80M
8.59%
77.63%
4.75%
Biotechnology
Pharmaceutical Preparations
Link
Netherlands
AMSTERDAM